strategic plan
Progenity to Close Genetics Lab as Focus Shifts to Therapeutics
The firm will no longer offer its Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, or Resura Prenatal Test.
Qiagen, NuProbe Partner on Rare Variant Enrichment in Liquid Biopsy Tests
The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.
CVS Health, Tempus Precision Oncology Program Aims to Aid Oncologists, Improve Patient Outcomes
Premium
The CVS-Tempus partnership aims to streamline the cancer care process for patients from the point of prescribing onwards and connect patients with local trials.
NIH Strategic Research Plan Aims to Improve Tickborne Disease Diagnosis, Detection
The plan focuses on five scientific priorities to advance research and development over the next five years, including developing diagnostic tests for the diseases.
Qiagen Partners With Illumina on NGS IVD Kits; CEO Departing; Preliminary Q3 Revenue Growth Lowered
Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.